Polymyxin B
| 證據等級: L5 | 預測適應症: 3 個 |
目錄
- Polymyxin B
- Polymyxin B: From Antibacterial Therapy to Bacterial Conjunctivitis, Bronchitis, and Laryngotracheitis
Polymyxin B: From Antibacterial Therapy to Bacterial Conjunctivitis, Bronchitis, and Laryngotracheitis
One-Sentence Summary
Polymyxin B is a polypeptide antibiotic historically used against gram-negative bacterial infections (no original indication record is available in this evidence pack). TxGNN predicts three potential new indications — bronchitis, laryngotracheitis, and conjunctivitis. Of the three, only bacterial conjunctivitis is backed by substantial evidence (3 clinical trials, including multiple Phase 3/4 RCTs, plus 20 publications, several of them head-to-head RCTs); the other two candidates currently have weak or no supporting evidence.
Quick Overview
Primary Candidate: Conjunctivitis (strongest evidence)
| Item | Content |
|---|---|
| Original Indication | Not available in evidence pack (no licenses/indication text on record) |
| Predicted New Indication | Conjunctivitis |
| TxGNN Prediction Score | 99.06% |
| Evidence Level | L1 |
| US Market Status | Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | Proceed with Guardrails |
All Predicted Indications — Comparison
| Rank | Indication | TxGNN Score | Evidence Level | Decision Stage | Recommendation |
|---|---|---|---|---|---|
| 1 | Bronchitis | 99.87% | L4 | S1 | Hold |
| 2 | Laryngotracheitis | 99.62% | L5 | S0 | Hold |
| 3 | Conjunctivitis | 99.06% | L1 | S3 | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this evidence pack (Data Gap). Based on general pharmacological knowledge, Polymyxin B is a cyclic polypeptide antibiotic that binds to lipopolysaccharide (LPS) in the outer membrane of gram-negative bacteria, disrupting membrane permeability and causing bacterial cell death. It is primarily active against gram-negative organisms such as Pseudomonas aeruginosa and Acinetobacter baumannii.
Conjunctivitis is the most mechanistically and clinically coherent candidate: topical Polymyxin B, usually combined with trimethoprim (e.g., Polytrim), is already an established treatment for bacterial conjunctivitis, and this evidence pack effectively documents confirmatory head-to-head trials against moxifloxacin rather than a truly novel indication.
Bronchitis evidence is mechanistically plausible (gram-negative tracheobronchitis, e.g., Pseudomonas/Acinetobacter VAP/VAT) but the literature is dominated by studies using inhaled Polymyxin B as a bronchoconstriction-provoking diagnostic agent rather than a therapeutic agent, and includes at least one inhalation toxicity case report — the treatment and adverse-event signals are mixed and inconsistent.
Laryngotracheitis has no clinical trial or literature evidence at all — the prediction rests solely on the TxGNN knowledge-graph score, with no way to independently assess plausibility beyond the general antibacterial mechanism.
Clinical Trial Evidence
Bronchitis
Currently no related clinical trials registered.
Laryngotracheitis
Currently no related clinical trials registered.
Conjunctivitis
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00581542 | Phase 4 | Completed | 124 | Head-to-head comparison of Polytrim (polymyxin B/trimethoprim) vs. moxifloxacin ophthalmic solution for pediatric conjunctivitis; both FDA-approved treatments compared for efficacy. |
| NCT01227863 | Phase 3 | Unknown | 70 | RCT comparing two dexamethasone+neomycin+polymyxin B combination products (Maxinom® vs Maxitrol®) for acute bacterial conjunctivitis; completion/publication status unconfirmed. |
| NCT01809483 | Phase 3 | Completed | 32 | Compared bandage contact lens vs. pressure patching for corneal erosion; polymyxin B likely used as background antibiotic rather than primary intervention — moderate relevance. |
Literature Evidence
Bronchitis (top 10 of 14 identified)
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 23124906 | 2013 | Cohort/Comparative | Infection | Compared polymyxin B with other antimicrobials for VAP/tracheobronchitis caused by P. aeruginosa or A. baumannii. |
| 17350201 | 2007 | Case series (salvage therapy) | Diagn Microbiol Infect Dis | Inhaled polymyxin B used as salvage treatment for pneumonia/tracheobronchitis from multidrug-resistant gram-negative bacilli (19 patients). |
| 4373513 | 1974 | Case series | J Kansas Med Soc | Pseudomonas tracheobronchitis treated with systemic gentamicin plus polymyxin B aerosol. |
| 4319158 | 1970 | Case series (experimental) | Chest | Endobronchial polymyxin B experimental observations in chronic bronchitis. |
| 4322737 | 1971 | Case report (adverse event) | Ann Intern Med | Reports danger/toxicity associated with polymyxin B inhalation — important safety counter-signal. |
| 231152 | 1979 | Provocation study (non-therapeutic) | Lung | Inhaled polymyxin B used to induce bronchial reactivity in asthma/chronic obstructive bronchitis (diagnostic, not therapeutic use). |
| 2984629 | 1985 | Provocation study (non-therapeutic) | Orvosi Hetilap | Polymyxin B sulfate-induced non-specific bronchial provocation in asthma/chronic bronchitis. |
| 7402949 | 1980 | Provocation study (non-therapeutic) | Pneumonologia Polska | Compared exercise-induced bronchospasm with histamine/polymyxin B provocation testing. |
| 8054833 | 1994 | Mechanism study | Clin Auton Res | Guinea-pig model of polymyxin B-induced eosinophilic bronchitis, used to study cough mechanisms. |
| 11359434 | 2001 | Mechanism study | Clin Exp Allergy | Polymyxin B-induced airway eosinophil accumulation and its effect on bronchial responsiveness in guinea pigs. |
Laryngotracheitis
Currently no related literature available.
Conjunctivitis (top 10 of 20 identified, RCTs prioritized)
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 19043943 | 2008 | RCT | J Pediatr Ophthalmol Strabismus | Moxifloxacin vs. polymyxin B/trimethoprim sulfate in pediatric bacterial conjunctivitis. |
| 19043945 | 2008 | RCT (multicenter) | J Pediatr Ophthalmol Strabismus | Multicenter comparison of speed of clinical efficacy: polymyxin B/trimethoprim vs. moxifloxacin. |
| 23092529 | 2013 | RCT (single-blind) | J Pediatrics | Moxifloxacin vs. polymyxin B-trimethoprim for acute conjunctivitis in children. |
| 6188739 | 1983 | RCT | J Antimicrob Chemother | Multicentre trial: trimethoprim-polymyxin B vs. neomycin-polymyxin B-gramicidin vs. chloramphenicol for presumptive bacterial conjunctivitis (230 patients). |
| 2540136 | 1989 | RCT (review of 4 studies) | J Antimicrob Chemother | Trimethoprim-polymyxin B vs. chloramphenicol ophthalmic ointment across 4 pooled RCTs (528 patients). |
| 2850891 | 1988 | RCT (double-blind) | Curr Med Res Opin | Trimethoprim-polymyxin B vs. chloramphenicol ointment; equally effective and well tolerated (42 patients). |
| 2370842 | 1990 | RCT | Med Lett Drugs Ther | Independent evaluation of trimethoprim-polymyxin B for bacterial conjunctivitis. |
| 11270936 | 2001 | Review | Drugs | Comparative review of topical ophthalmic antibacterials; notes polymyxin B’s selectivity for gram-negative species. |
| 16491721 | 2006 | Review/Guidance | J Pediatr Ophthalmol Strabismus | Guidance on controlling contagious bacterial conjunctivitis outbreaks, including antimicrobial selection. |
| 8595639 | 1995 | Cohort/Survey | Clin Ther | Survey of children with acute bacterial conjunctivitis treated with trimethoprim-polymyxin B ophthalmic solution. |
US Market Information
Currently no US market authorization records available (total_licenses = 0, market status: Not Marketed).
Safety Considerations
Please refer to the package insert for safety information. No key warnings, contraindications, or drug interaction data are currently available in this evidence pack (flagged as a Blocking data gap — TFDA/label warnings and contraindications — see Next Steps below).
Conclusion and Next Steps
Decision: Proceed with Guardrails — Conjunctivitis only. Hold on Bronchitis and Laryngotracheitis.
Rationale:
- Conjunctivitis: Multiple Phase 3/4 RCTs and a substantial RCT literature base (7+ RCTs) directly compare polymyxin B-containing products against established comparators (moxifloxacin, chloramphenicol). This largely confirms an already-recognized use rather than a purely novel prediction, so guardrails (safety/label confirmation) rather than full development are appropriate.
- Bronchitis: Evidence is mechanistically plausible but inconsistent — most studies use inhaled polymyxin B as a diagnostic bronchoprovocation agent, not a therapeutic agent, and at least one adverse-event case report raises safety concerns. Insufficient to proceed.
- Laryngotracheitis: No clinical trial or literature evidence exists; the prediction is model-score-only (L5). Not actionable at this time.
To proceed, the following is needed:
- TFDA label warnings/contraindications (currently a Blocking data gap — required before any S1 safety screening)
- Confirmed mechanism of action (MOA) documentation from DrugBank (High severity gap — needed for mechanistic-link validation)
- Confirmation of completion/publication status for NCT01227863 (currently “Unknown”)
- If pursuing bronchitis further: independent therapeutic (non-provocation) efficacy data and formal safety assessment of inhaled use, given the existing toxicity case report
- No further action recommended for laryngotracheitis unless new clinical or literature evidence emerges
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.